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Abstract
Prion diseases are fatal neurodegenerative disorders causing motor dysfunctions, dementia and neuropathological changes
such as spongiosis, astroglyosis and neuronal loss. The chain of events leading to the clinical disease and the role of distinct
brain areas are still poorly understood. The role of nervous system integrity and axonal properties in prion pathology are still
elusive. There is no evidence of both the functional axonal impairments in vivo and their connection with prion disease. We
studied the functional axonal impairments in motor neurons at the onset of clinical prion disease using the combination of
tracing as a functional assay for axonal transport with immunohistochemistry experiments. Well-established and novel
confocal and ultramicroscopy techniques were used to image and quantify labeled neurons. Despite profound differences
in the incubation times, 30% to 45% of neurons in the red nucleus of different mouse lines showed axonal transport
impairments at the disease onset bilaterally after intracerebral prion inoculation and unilaterally—after inoculation into the
right sciatic nerve. Up to 94% of motor cortex neurons also demonstrated transport defects upon analysis by alternative
imaging methods. Our data connect axonal transport impairments with disease symptoms for different prion strains and
inoculation routes and establish further insight on the development of prion pathology in vivo. The alterations in
localization of the proteins involved in the retrograde axonal transport allow us to propose a mechanism of transport
disruption, which involves Rab7-mediated cargo attachment to the dynein-dynactin pathway. These findings suggest novel
targets for therapeutic and diagnostic approaches in the early stages of prion disease.
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Introduction
Prion diseases, for example Bovine Spongiform Encephalopathy
(BSE) or Creutzfeldt-Jakob disease (CJD), are lethal neurodegener-
ative disorders caused by the abnormal form (PrP
Sc) of host prion
glycoprotein (PrP
C). Spongiform vacuolations, accumulation of
PrP
Sc-rich amyloid fibrils, neuronal cell loss, microglial activation
and proliferation of astrocytes in the central nervous system (CNS)
are typical neuropathological hallmarks [1], which do not always
temporally correlate with clinical disease symptoms. Mice bearing
one disrupted allele of the PrP gene (Prnp
0/+) develop scrapie
symptoms 290 days post intracerebral (i.c.) prion inoculation (dpi),
whereaswild-typemice(wt) develop symptomsat158 dpi.However
both mouse lines demonstrate a similar neuropathology already at
140 dpi [2]. In addition, immunodeficient mice show neuropath-
ological changes in the CNS, but develop no clinical symptoms after
prion infection [3]. Transgenic mice expressing truncated PrPD32-
93 (C4/C4) demonstrate no detectable brain pathology upon prion
challenge but develop clinical symptoms along with 10–25%
neuronal loss in the spinal cord [4].
The study with PrPD32-93 mice (C4/C4) implicates that prion-
induced impairments and neuronal loss in the spinal cord are
sufficient to cause prion disease. The impairments of axon
functions such as synaptic degeneration, protein accumulation
and changes of microtubule distribution were detected in CJD
patients [5,6], in animal [7] and in vitro [8] models of prion disease.
However, other studies implied that the transport may not play a
key role in prion pathology [9,10] so that the role of axonal
transport still remains elusive.
A growing line of evidence shows that axonal impairments are
associated with different neurodegenerative disorders, e.g. Hunting-
ton’s disease [11]. In Alzheimer’s disease (AD), such defects as axonal
swellings containing abnormally accumulated proteins, impaired
axonal transport with reduced kinesin levels preceded the disease-
related pathology in mouse models and in human patients [12].
In this study, we applied axonal tracing as a functional assay for
the retrograde transport in five different wild type and transgenic
mouse lines. A correlation between impairments in retrograde
axonal transport and onset of clinical prion disease was
demonstrated independently on incubation time and prion strain
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symptoms. The combination of prion inoculation into a distinct
group of motor neurons with differential localization of proteins
involved in the transport processes connects impairments in
retrograde axonal transport with prion pathogenesis and suggests
molecular mechanism for this process. These findings suggest
novel targets for therapeutic and diagnostic approaches in the
early stages of prion disease.
Results
Axonal tracing of prion-challenged mice
The primary objective of our study was to find the molecular
mechanisms responsible for the clinical symptoms of prion disease
including the motor system defects, such as ataxia and partial
hindlimb paralysis [1]. We supposed that the connection between
the central nervous system and motor system and, in particular,
axonal transport may play a role in prion pathogenesis. Axonal
transport was studied in rubro- and corticospinal motor neurons in
mouse models for prion disease using retrograde axonal tracing.
Wild type (wt) and different transgenic mice were challenged with
prions intracerebrally (i.c.) or in the right sciatic nerve (intraner-
vously, i.n.). Prior to the onset of clinical disease, either Fast Blue
(FB) [13] or Adeno-Associated Virus expressing DsRed-Express
(AAV-REx) was injected into the spinal cord. The tracers were
retrogradely transported along axons to label motor neurons of
distinct brain regions including the red nucleus (RN) and motor
cortex (Figure 1A). Both FB and AAV-REx application did not
influence prion disease progression (data not shown). Great care
was taken to standardize the quantification of neuron. The
anatomical location was verified by staining serial coronal sections
with the neuronal marker NeuN (Figure 1B) and co-localization of
tracer deposits with NeuN signal. Only large tracer-positive
pyramidal motor neurons in the RN were quantified using the
analysis of z-stacks done on serial coronal cryo-sections (Figure 1C
and D). The proper localization of the RN was also re-verified by
staining with Wisteria floribunda agglutinin (WFA, Figure 1E), a
marker for extracellular proteoglycans at the neuronal surface of
RN neurons, but not for neighboring tissue [14,15].
Distribution of Fast Blue in the red nucleus following
intracerebral prion infection
A bilateral decrease of FB-positive neurons as compared to mock
controls was detected in the RN of five different wt and transgenic
mouse lines challenged with prions i.c. Despite differences in the
incubation times (Table S1), a 43–45% reduction was observed for
wt and Tga20 mice. C4/C4 transgenic mice, which demonstrate no
typical neuropathology [4] showed a significant 30% decrease of
tracer-positive cells in the RN (Figure 1F). Axonal tracing of Prnp
0/+
mice was performed at 270 dpi and at 330 dpi immediately after
onset of clinical disease (32262 dpi), and at 370 dpi. A 38%
reduction of FB-positive neurons at 270 dpi and a 45% reduction at
330 dpi (similar to wt and Tga20) were counted in the RN. Scrapie-
diseased Prnp
0/+ animals at 370 dpi demonstrated a 49% decrease
of FB-positive neurons in the RN (Figure 1F and Table S1), which
indicated a gradualreductionofRNneuronspossessing functionally
intact projections into the spinal cord during disease development.
To clarify whether the decrease of tracer-positive neurons
implicating functional impairments in axonal projections is specific
for RML prions only, we also applied FB to hamster-adapted
transgenic mice Tg(SHaPrP), which were challenged with Sc237
hamster prions. A 43% bilateral decrease of FB-positive cells was
observed in the RN (Figure 1F and Table S2) of these mice
following i.c. prion infection.
These results demonstrated that despite differences in the
incubation times, the bilateral reduction of FB-positive neurons
with intact axonal transport correlated with the onset of the
clinical symptoms after intracerebral prion challenge. The
proportion of affected neurons increased gradually and reached
a level of 30–45% at the disease onset independent of the mouse
line and prion strain.
Distribution of Fast Blue in the red nucleus following
prion infection in the sciatic nerve
In order to assess axonal transport upon selective inoculation
into distinct groups of motor neurons, prions were applied into the
right sciatic nerve (i.n.). Anatomically, about 90% of RN neurons
project to the contralateral side. I.n. inoculation resulted in the
initial prion distribution on the contralateral RN followed by
bilateral accumulation in the RN, hindlimb motor cortex and
thalamus at the terminal stage of the disease [16,17]. The bilateral
prion accumulation upon unilateral i.n. challenge was also recently
demonstrated in our lab for the RN and MC at both onset and
terminal stage of clinical disease [18], which is in agreement with
the data on i.n. inoculations from other groups [16,17]. Moreover,
similar neuropathological features, such as spongiosis and
activation of astrocytes were also observed in the RN bilaterally
(Figure S1). Surprisingly, upon application of FB shortly before the
onset of disease symptoms, a 43% and 37% reduction of FB-
positive cells was found exclusively on the contralateral RN side in
wt and Tga20 mice, respectively. C4/C4 transgenic mice showed
a 33% unilateral decrease of FB-positive neurons, which
correlated with the unilateral reduction for wild-type (wt) and
Tga20 animals. A 28% unilateral decrease of FB-positive cells was
also observed in the RN of Tg(SHaPrP) mice upon i.n. challenge
with hamster prions (Figure 2A and Tables S2 and S3).
In order to understand whether prion challenge affects only the
retrograde transport mechanism utilized by FB, we exactly
reproduced the tracing experiment on i.n. challenged wt and
Author Summary
For almost a century, prion disease symptoms, such as
dementia and motor system defects, have been accom-
panied with neuropathological hallmarks in the central
nervous system. In past decades, discrepancies between
neuropathological changes and clinical symptoms showed
that the processes triggering the disease remain elusive.
We concentrated on the hypothesis that nervous system
integrity and axonal properties may play an important role
in the disease development. Since motor system defects
are typical for prion disease, we investigated the centers of
the motor system, red nucleus and hindlimb area of motor
cortex. Although intracerebral prion infection led to a 30%
to 45% bilateral reduction of labeled neurons in the red
nucleus, infection into the right sciatic nerve—the major
hindlimb nerve—led to unilateral reduction of labeled
neurons in the red nucleus. Up to 94% reduction was
found in the neurons of motor cortex hindlimb area. This
reduction is probably caused by functional axonal
impairments in motor neurons. Prion-induced alterations
in protein distribution implicate a mechanism of transport
disruption at cargo attachment to the retrograde axonal
transport complex. Our work reveals a connection
between axonal transport impairments and disease
symptoms in vivo, providing further insight in the
development of prion pathology and suggesting novel
targets for therapeutic and diagnostic approaches.
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[19,20,21] expressing the fluorescent marker DsRed-Express
(REx). The numbers of FB- and REx-labeled neurons did not
significantly differ for the mock controls. Moreover, REx and FB
co-localized in the RN neuronal cells after injection into the spinal
cords of the same animals (data not shown). Similar to FB, the
difference between contra- and ipsilateral sides upon i.n. prion
challenge could be clearly seen on the same z-stacks done on RN
section of i.n. challenged mice but not of mock controls (Figure 2B).
The quantification of REx-positive neurons for wt and Tga20
mice revealed a 39% and 49% decrease of tracer-positive neurons
on the contralateral side of the RN, respectively (Figure 2C and
Table S4). The reduction of tracer-positive neurons initially
demonstrated for FB was confirmed for AAV-REx. The tracing
experiment at 50% of incubation time (at 82 dpi upon i.n.
challenge) demonstrated no significant differences of labeled RN
neurons with mock controls, which reveals the important role of
this center in the development of the disease and supports the view
that appearance of the axonal transport impairments in the RN
neurons is connected with the disease onset.
Our system combining unilateral inoculation of prions into the
right sciatic nerve and axonal tracer application enabled
investigation of axonal defects specifically connected with prion
pathogenesis. The ipsilateral side of the RN did not show any
significant decrease of tracer-positive neurons and could be used as
an internal control. The differences between the ipsilateral site and
the contralateral – initially targeted with prions were directly
observed on the same z-stack done on serial cryo-sections of i.n.
challenged mice but were not detectable in the mock controls.
Moreover, on the contralateral side of the RN, we observed a
fraction of NeuN-positive neurons, which did not contain FB
(Figure 3A, asterisks). In contrast, the ipsilateral RN did not
Figure 1. Quantification of retrogradely labeled neurons reveals significant alterations upon prion challenge. (A) Mice were
challenged with prions intracerebrally (prions i.c.) or into the right sciatic nerve (prions i.n.). The axonal tracers were applied into the spinal cord
before the onset of clinical disease. Retrogradely labeled tracer-positive neurons were quantified in the red nucleus (RN) and motor cortex (MC). (B)
The NeuN-positive neurons in the RN (within the dashed line). The RN is a clearly defined center in the midbrain. It is divided into two parts,
magnocellular (RMC) and parvicellular (RPC) in the section shown. Small box: anatomic localization of RN on coronal brain section stained with
hematoxilin-eosin. (C) Enhanced part of B. The large pyramidal motor neurons projecting via spinal cord were quantified (arrows), but not the smaller
ones (asterisks). Scale Bar: 100 mm (D) Fast Blue-positive neurons in the RN. The big pyramidal cells possessed several deposits of FB in the cytoplasm
(arrows) and were quantified on z-stacks done on serial cryo-sections. Analysis of z-stacks allowed us to reliably rule out the artifacts (asterisks) from
the quantification. Scale bar: 100 ml. (E) Wisteria floribunda agglutinin-positive cells are typical for the RN and a proof for the correct localization of
tracer-positive neurons. (F) Bilateral reduction of FB-positive (FB+) neurons was observed in the RN of different mouse lines upon intracerebral (i.c.)
prion challenge. FB was applied at indicated number of days post prion inoculation (dpi). For the times of disease onset and terminal stage as well
as numbers of quantified neurons, see Tables S1 and S2. M – mock, wt – wild type. Unpaired t-test was done using GraphPad Prism software. ***
–P ,0.0001, * – P,0.02.
doi:10.1371/journal.ppat.1000558.g001
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(Figure 3A, arrows; for overview, see Figure S2). This observation
was confirmed on both visual and computerized co-localization
analysis. Due to high background we still observed the fluorescent
objects in the vicinity of NeuN-positive cells on the contralateral
RN, which were not perfectly co-localizing. In order to perform
systematic stereological analysis, we defined Regions of Interest
(ROI) according to the NeuN-positive fluorescence in several
mock and i.n. samples (Figure S3A) and quantified the FB
fluorescence as a per cent of the NeuN fluorescence in z-stacks
using available software tools. The analysis of more than 150 cells
from 3 i.n. and 4 mock samples revealed practically all the cells in
mock controls to contain FB fluorescence over 18% to the level of
NeuN signal, which was over the calculated background value of
17%. Fourty-four per cent of the cells in the contralateral RN (21
of 47 totally analyzed) demonstrated the relative FB fluorescence
under the background level, and only 7% (3 of 40 analyzed) – in
the ipsilateral RN (Figure 3B).
To further understand whether the reduction of the tracer-
positive neurons can be explained by the neuropathological
changes leading to the neuronal disruption, we quantified the
NeuN-positive cells in the RNs of sampled mock (n=3) and i.n.
challenged (n=4) mice. We did not observe significant differences
in NeuN-positive cells between mock and i.n. inoculated mice
despite very clear difference in REx-positive cells (Figure 3C and
Table S5). Taken together, this data implies that the decrease of
tracer positive cells upon prion challenge cannot be simply
explained by neuronal loss but by the impairments in the delivery
of transported cargo – the FB molecules or AAV-REx.
The dramatic reduction of tracer-positive neurons indicated
functional impairments of retrograde transport in the RN neurons.
These impairments occurred bilaterally upon i.c. and unilaterally –
upon i.n. prion challenge. However, the accumulation of PrP
Sc and
neuropathological changes were observed in the RN bilaterally also
upon i.n. inoculation [16,18]. In order to clarify whether the
decrease of tracer-positive neurons directly reflected the fraction of
Figure 2. Unilateral decrease of tracer-positive neurons after prion inoculation in the sciatic nerve. Different wild type (wt) and
transgenic mouse lines were infected with prions unilaterally in the right sciatic nerve (i.n.) and the tracer was injected in the cervical spinal corda t
indicated days post prion challenge (dpi). For the times of disease onset and terminal stages as well as exact numbers of quantified neurons, see
Tables S2, S3 and S4. (A) A reduction of Fast Blue-positive neurons (FB+) was demonstrated in the contralateral (c), but not on the ipsilateral (i) RN as
compared to the mock controls. (B) The profile of the REx-positive cells differed between contralateral and ipsilateral RN upon i.n. prion inoculation,
but not in mock controls. Shown here are the RNs of the Tga20 mice, which injected with AAV-REx at 145 dpi and sacrificed at the terminal stage of
the disease. (C) Reduction of REx-positive neurons on contralateral RN was observed in Tga20 and wt mice at the onset of prion disease (54 and
136 dpi after i.n. prion inoculation, respectively), but not at 50% of incubation time (82 dpi). Non-paired t-test was done with GraphPad Prism
software. *** – P,0.0001, ** – P=0.001, * – P=0.04, NS – non-significant.
doi:10.1371/journal.ppat.1000558.g002
Impaired Axonal Transport in Prion Disease
PLoS Pathogens | www.plospathogens.org 4 August 2009 | Volume 5 | Issue 8 | e1000558the PrP
Sc-containing neuronal perikarya, we performed co-
localization experiment and analysis of PrP
Sc and REx in the RN
of i.n. prion-challenged wt mice. The fraction of the REx-positive
cells co-localized with PrP
Sc at the onset of clinical prion disease
(152 dpi, Figure 4, arrows), but the rest of REx-positive cells was
PrP
Sc-negative (Figure 4, asterisks). This experiment implies that
PrP
Sc possibly does not switch off the axonal transport in a trigger-
like manner upon arrival in the somas of RN neurons, but likely
initiates a gradual decrease of transport functions in axons during
the neuroinvasion process. This assumption is also supported by the
gradual decrease of tracer-positive neurons in Prnp
0/+ mice upon i.c.
prion challenge (Figure 1F).
Reduction of DsRed-Express-positive neurons in the
motor cortex
Inoculation into the right sciatic nerve results in a bilateral prion
distribution in the MC, the brain center responsible for voluntary
movements in rodents and humans. To assess retrograde axonal
transport in this area, we compared REx-positive neurons in MC
of mock- and prion-inoculated mice using confocal microscopy
and our custom-built ultramicroscopy system [18]. Significant
differences in REx-positive cells were not detected in wt mock
controls, but the difference to prion-challenged animals was clearly
visible (Figure 5A). Ultramicroscopy is a method significantly
differing from confocal imaging. It requires no cryo-sectioning and
allows for imaging of the large region in the MC. Similar to
confocal microscopy, ultramicroscopy revealed clearly visible
reduction of REx-positive neurons in the MC of wt mice
inoculated with prions i.n. as well as i.c. as compared to the
mock controls (Figure 5B and [18]). The quantification of the
REx-positive neurons in the hindlimb area of the MC was done on
combined confocal images.
Extra precautions were taken to assure accurate and standard-
ized area localization as well as reliable and uniform quantification
and analysis of labeled cells. The confocal stacks were simulta-
neously contrasted and thresholded, and the REx-positive cells
were quantified within the same combined stack. This approach
ruled out the possible artifacts between mock and infected samples
Figure 3. Reduction of tracer-positive cells in the red nucleus is not attributed to neuronal loss. (A) Co-localization of FB (green) and
NeuN (red) analysis in the contralateral and ipsilateral RN of mice upon prion challenge in the sciatic nerve (i.n.) done at the onset of clinical disease
(152 dpi). A population of viable NeuN-positive cells is FB-negative (asterisks), which implicates the defects in axonal transport. In other cells NeuN
and FB co-localize (arrows, yellow). Scale bars: 50 mm. (B) Distribution histogram of the relative FB to NeuN fluorescence analyzed on z-stacks in the
Regions of Interest (ROI). The analysis quantitatively demonstrates that FB fluorescence co-localizes with NeuN in mock controls. 44% of contralateral
neurons was below the background threshold and considered FB-negative, and 7%—on the ipsilateral RN. (C) Quantification of NeuN-positive
neurons in the sampled mock and i.n. mice revealed no differences between mock and inoculated animals despite the reduction of REx-positive cells.
Unpaired t-test was done using GraphPad Prism software. *** – P,0.0001. NS – non-significant.
doi:10.1371/journal.ppat.1000558.g003
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procedure was normalized according to the REx deposit
properties assessed by co-localization with the NeuN neuronal
marker as was demonstrated earlier [18]. A remarkable 9463%
bilateral reduction of REx-positive neurons was found in the MC
of i.n. challenged wt mice (n=4). Surprisingly, the tracing
experiment with wt animals at 50% of incubation time (82 dpi)
demonstrated the reduction of the tracer-positive neurons
(9561%, n=3) similar to the one obtained immediately prior to
the onset of the clinical disease (Figure 5C). Previously, we already
demonstrated that both methods of confocal and ultramicroscopy
revealed quite similar reduction of tracer-positive neurons in the
same MC regions at the onset of prion disease [18]. Moreover, we
also showed that the number of NeuN-positive neurons was not
affected at the onset of clinical prion disease upon i.n. challenge in
the MC [18]. This experiment rules out the possibility that the
massive reduction of tracer-positive cells can be attributed to the
neuronal loss upon prion challenge.
Alternative hypotheses for labeled neuron decrease
The decrease of tracer positive neurons implies impairments of
axonal transport caused by the prion infection. However, there are
alternative explanations of observed phenomenon. The possibility
that the observed reduction of tracer positive cells can be
explained by the reduction of neurons in the RN and MC seems
not very plausible because of comparable number of NeuN
positive neurons in the RN (Figure 3A) and MC [18]. A further
hypothesis implies that the observed decrease could be attributed
to the altered tracer uptake or altered number of axons in the
cervical spinal cord at the injection site. Earlier we demonstrated
that ultramicroscopy z-stacks of REx-positive neurons in the
cervical spinal cord immediately cranially to the tracer injection
site do not differ between mock controls and i.n. infected mice
[18]. In order to demonstrate, whether the axons in the spinal cord
white matter are altered upon prion challenge, we performed
Toluidine Blue staining. Toluidine Blue stains myelin sheath
visualizing neuronal projections in the spinal cord. The Toluidine
blue staining showed no significant differences between spinal cord
samples of mock and prion-infected mice. Some axonal swellings
were observed in the spinal cord and represent the variable axon
caliber resembling to our knowledge the typical appearance of
myelinated and non-myelinated axons. Furthermore, since these
swellings appear not only in the spinal cords of prion-infected, but
also of the mock animals, and since they are not restricted to the
rubro- or corticospinal tracts, we assume that they probably could
be partially attributed to experimental artifacts, for example as a
result of tracer injection. A certain degree of axonal degeneration
upon prion infection, however, cannot be absolutely excluded with
these experiments.
Altered distribution of marker proteins upon prion
challenge
Further, we aimed to clarify whether the transport impairments
documented by the altered delivery of the retrograde cargo – the
FB or AAV-REx – can be characterized by the changes in protein
distribution. The localization of various proteins either previously
connected with prion pathology or involved in the retrograde
transport processes was analyzed using immunohistochemistry.
AAV enter the cells via clathrin-mediated endocytosis upon
binding to the heparan sulfate proteoglycan. After entering the
neuronal cell, AAV particles are internalized into Rab7-positive
late endosomes. Rab7 mediates the endosome binding to the
dynein-dynactin complex via the p150
GLUED protein and are
retrogradely transported towards neuronal bodies [22]. We
analyzed the distribution pattern for Rab7, a protein responsible
for recruitment of late endosomes into the retrograde transport
pathway. In the RN of i.n. prion-challenged animals at the onset of
prion disease (at 152 dpi) the pattern of Rab7 distribution was
diffuse, sometimes in the close vicinity or within the REx-positive
cells (Figure 6A). In the mock controls Rab7 immunoreactivity
concentrated mostly in the neuronal projections not co-localizing
with REx-positive neurons (Figure 6B). The analysis of prion
infected mice demonstrate that Rab7 did not directly co-localize
with REx but was located in the vicinity of it in the RN cells, but
not of mock controls. We performed analysis of relative
fluorescence of Rab7 on confocal z-stacks in the ROIs defined
according to the REx-positive neurons (Figure S3B). The Rab7
fluorescence was quantified as per cent to the REx signal in the
same cell volume. The Rab7 fluorescence was not present in the
REX-positive cells of mock controls (0.760.3% of REx fluores-
cence intensity). The REx-positive cells of i.n. infected mice did
contain a lot of Rab7 signal, in ipsilateral RN (29.868.9%) and
especially in contralateral RN cells (75.4644.6%) (Figure 6C).
The staining for the p150
GLUED protein involved in the binding
of late endosomes to the dynein-dynactin transport complex
demonstrated a bilateral decrease of immunoreactivity in the RN
Figure 4. Co-localization analysis of REx and PrP
Sc. Co-
localization analysis of REx (green) and PrP
Sc (red, stained with ICSM35
antibodies) in the RN of wt mice was done at 152 dpi upon i.n. prion
inoculation. In a certain cell population of REx and PrP
Sc co-localize
(arrows, yellow). Other cells are REx-positive but do not contain PrP
Sc
(asterisks). Scale bars: 50 mm.
doi:10.1371/journal.ppat.1000558.g004
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(Figure S4).
Highly aggregated PrP
Sc deposits were shown to be ubiquiti-
nated in axons as well as neuronal bodies of CJD patients [6].
Analysis of MC cryo-sections stained with anti-ubiquitin antibod-
ies revealed 2.5-fold enhanced ubiquitination at the onset of
clinical disease (152 dpi) after i.n. prion challenge as compared to
the mock controls (Figure 7A). This data indicated induced protein
degradation processes in the PrP
Sc-containing hindlimb area of
MC, which also contained neurons with axonal transport defects.
Activation of different forms of Notch protein (Notch-1, Notch-
2 etc.) inhibits axonal growth during neuronal development as well
as elaboration and maintenance of mature axons [23,24].
Increased levels of the Notch-1 intracellular domain (NICD) were
also detected in the neurons of prion-infected mice [25]. Upon
analysis of the MC cryo-sections stained with anti-Notch-1
antibodies we found 6-fold elevated levels of NICD at the onset
of clinical disease (152 dpi) in the MC of i.n. inoculated animals as
compared to the mock controls (Figure 7B), which indicated
possible disruption of axonal maintenance upon prion challenge.
The staining for dynamitin, a component of the dynein-
dynactin transport protein complex, however, did not reveal any
differences between prion-challenged and mock mice (Figure S5).
This data confirms the previous observation that mice bearing
mutation in the cytoplasmic dynein do not show any differences in
prion disease incubation time nor neuropathology as compared
with wild type littermates [9].
Discussion
Axonal transport is a process important for neuronal viability
and differentiation. It is often impaired during development of
various neurodegenerative diseases, such as AD or amyotrophic
lateral sclerosis [26]. Several experimental reports performed with
animal models of prion disease [7,8] or based on the analysis of
CJD patients [5,6,27,28] implied general axonal defects, such as
axonal swellings or altered distribution of transport-related
proteins possibly contributing to prion pathogenesis, but did not
establish a correlation between axonal impairments and clinical
symptoms, nor demonstrated any functional axonal impairments
in vivo. Other studies, however, suggested no correlation between
axonal transport and prion disease [9,10].
The RN is a part of the extrapyramidal motor system, along
with cerebellum, substantia nigra and other brain centers as well as
rubrospinal tract. A great majority of the extrapyramidal neurons
project via the rubrospinal tract on the contralateral side. The MC
belongs to the pyramidal motor system, which innervate the
muscles via the brainstem or spinal cord. The neurons in the RN
Figure 5. Reduction of DsRed-Express-positive neurons in motor cortex. (A and B) Bilateral reduction of REx-positive neurons in the motor
cortex (MC) of wild type (wt) mice upon prion challenge into the right sciatic nerve (prions i.n.) or intracerebrally (prions i.c.), as compared to mock
controls, shown with confocal microscopy (A) and ultramicroscopy (B). (C) Quantification of REx-positive neurons on confocal images of MC shows a
9463% (n=4) reduction of tracer-positive cells in the MC of wt mice inoculated with prions i.n. at the disease onset (AAV-REx application at 136 days
post prion inoculation, dpi) and a 9561% reduction (n=3) at 50% of incubation time (AAV-REx application at 82 dpi). Unpaired t-test was done using
GraphPad Prism software. *** – P,0.0001. NS – non-significant. Scale bars: 100 mm.
doi:10.1371/journal.ppat.1000558.g005
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right and left sides. Despite the complexity of the neuronal
connections we detected the reduction of the tracer positive
neurons bilaterally upon the i.c. prion infection, but unilaterally in
the RN of mice unilaterally challenged in the sciatic nerve. This
reduction also seemed to correlate well with the appearance of
clinical symptoms. The clinical symptoms in the Tga20 mice, such
as hindlimb paralysis, had clear unilateral character. The other
mouse lines, however, showed much more balanced motor system
defects. Such reductions were observed at the onset of clinical
prion disease in five different mouse lines despite very different
incubation times (5961 to 32262 dpi for Tga20 and Prnp
0/+ mice,
respectively). The observed defects were independent on prion
strain and inoculation route (Figures 1F, 2A, 2B). The reduction of
tracer-positive neurons could not be explained simply by the loss of
neuronal cells. We observed a fraction of NeuN-positive neurons
in the RN to be FB-negative implying the axonal transport
impairments in viable neurons (Figure 3A). Moreover, the
quantification of NeuN-positive neurons revealed no difference
between prion-infected and mock mice neither in the RN
(Figure 3C) nor in the MC [18]. The reduction of tracer-positive
neurons very likely implies the functional impairments of the
axonal transport in the living cells. An alternative hypothesis,
which suggests alterations in the tracer uptake, deposition or, in
the case of AAV-Rex, expression could be ruled out since
differences in spinal cord REx profiles between i.n. infected and
mock mice could not be observed [18]. Prion-induced changes in
the axons could also make further possible input in a reduction of
labeled neurons. The Toluidine Blue staining of axonal myelin in
the spinal cord did not demonstrate significant differences between
mock controls and i.n. challenged mice. We observed certain
axonal swellings, which can be partially attributed to the
experimental artifacts (Figure S6). Despite a certain degree of
axonal degeneration could not be absolutely ruled out, it cannot
explain prion-induced reduction of the labeled neurons. More-
over, since the tracer-positive neuron profile in the RN upon
intramuscular AAV-REx application (Ermolayev et al., unpub-
lished results) is not different from the results upon the AAV-REx
application in the cervical spinal cord, we assume that axonal
degeneration probably does not play a critical role in prion
pathogenesis.
We believe that the observed reduction of tracer-positive
neurons in the RN and MC could be most probably explained
by the functional impairments in axonal transport. Since the
Figure 6. Co-localization analysis of Rab7 and REx in the red nucleus of wild type mice. Co-localization analysis of Rab7 (red) and REx
(green) was performed in the red nucleus (RN) of wild type (wt) mice upon i.n. prion challenge (A) or in mock controls (B). Rab7 in mock controls was
localized mostly in the neuronal projections (arrows), but not in the vicinity of RN neuronal somas. Upon prion challenge Rab7 localization was more
diffuse. Rab7 was also localized in the vicinity of REx deposits within the same cells (asterisks). (C) Analysis of Rab 7 and REx fluorescence within the
regions of interest (ROI) defined in the contralateral and ipsilateral RN of animals infected with prions i.n. or in mock controls. Unpaired t-test was
done using GraphPad Prism software. *** – P=0.0003, ** – P=0.0077, * – P=0.0460. Scale bars: 50 mm.
doi:10.1371/journal.ppat.1000558.g006
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reduction of tracer-positive cells in the RN of different mouse
lines, we find that impairments of axonal transport belong to a
general phenomenon and are not limited to a certain type of
neuronal cells or represent a restricted subset of retrograde
transport pathways.
PrP
Sc probably initiates a process of gradual axonal transport
disruption, which could be demonstrated by the gradual decrease
of FB-positive neurons in Prnp
0/+ heterozygous mice (Figure 1F) as
well as from the observation that PrP
Sc partially colocalizes with
the tracer-positive cells in the RN (Figure 4).
We found altered localization of Rab7 and p150
GLUED, proteins
involved in retrograde axonal transport (Figure 6 and Figure S4,
respectively) in the RN of prion-challenged mice. Since the
dynamitin localization remains unaffected (Figure S5), it could be
assumed that the dynein-dynactin transport complex itself is not
affected during prion pathogenesis, which is consistent with
previously reported data [9]. Moreover, since map-2 and tau
distribution remains unaffected in prion-infected as compared to
mock animals (data not shown) as well, it could be assumed that the
microtubule network and dynein-dynactin retrograde transport
complex remain unaffected. The attachment of the cargo to this
complex, however, may represent a target of early prion
pathogenesis, which is supported by the altered distribution of
Rab7 and p150
GLUED proteins, which are either involved in the
recruitment of the vesicles into the dynein-dynacting pathway [26],
or directly involved in the attachment of the cargo to it [22]. The
p150
GLUED distribution is bilaterally diminished. The pattern of
Rab7 immunoreactivity is altered bilaterally. However, the
quantitative stereological analysis reveals that the neurons in the
contralateral RN show 2.6-fold more Rab7 in the neuronal bodies
at the onset of clinical prion disease. These data point on the
Figure 7. Altered protein expression in motor cortex upon prion challenge into the sciatic nerve. The wild type mice were analyzed at
the time point before the onset of clinical disease (145 dpi) upon prion challenge into the sciatic nerve. (A) Bilaterally, a 2.5-fold enhanced ubiquitin
expression was detected in motor cortex (MC) of prion-challenged mice as compared to mock control. NC – negative control with omitted primary
antibodies. (B) Bilaterally, a 6-fold enhanced Notch expression was detected in the MC of prion-challenged mice as compared to mock control. NC –
negative control with omitted primary antibodies. Scale bars: 100 mm.
doi:10.1371/journal.ppat.1000558.g007
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induced pathological changes.
The cells in the hindlimb area of MC demonstrated enhanced
protein degradation in prion-challenged mice at the onset of
clinical disease, which was indicated by elevated ubiquitin level
(Figure 7A). The bilateral 6-fold activated Notch-1 expression in
the hinlimb area of MC also at the onset of the disease (Figure 7B)
suggested impairments in the axonal maintenance as a component
of prion pathogenesis. Along with elevation in the experimental
model of prion disease [25], Notch expression was reported to be
up regulated also in the brains of AD patients [29]. AD is a
neurodegenerative disease, which was recently also connected with
axonal dysfunctions [12].
The tracing experiment performed at 82 dpi (50% of incubation
time upon i.n. prion challenge) did not reveal the differences of
REx-positive neurons in the RN between prion-infected animals
and mock controls (Figure 2C). Surprisingly, in the MC of the
same mice we detected as many impaired neurons as in the
animals immediately before the onset of the clinical disease
(Figure 5C). Similar proportions of damaged cortical motor
neurons at the onset of the disease and at 50% of incubation time
demonstrate that dramatic alterations in the hindlimb area of the
MC can still be compensated. The RN along with other brain
centers in rodents such as cerebellum is responsible for muscle
coordination during the movements. Since axonal transport
defects in RN neurons appear at the onset of clinical disease,
but not at the 50% of incubation time, we assume that this center
plays a critical role in the development of clinical symptoms.
Possibly, the RN plays a role of so-called ‘‘clinical target areas’’,
the regions required for the clinical disease development [30]. The
other brain centers involved in the movement coordination may
also play a role in prion pathogenesis, but their study was not the
goal of this report. The preferential role of certain brain areas was
also observed for other neurodegenerative diseases, for example
certain population of cholinergic neurons in AD [31].
The present study shows that the reduction of labeled neurons
in the RN and MC are caused by the prion-induced impairments
of retrograde transport in the axons projecting via spinal cord.
Such impairments in the RN neurons temporally correlate with
clinical symptoms of the disease, such as ataxia and hindlimb
paralysis, in five different mouse lines and different prion strains
independently on the inoculation route. We postulate a crucial
role of certain brain centers, e.g. RN, in prion pathogenesis. The
marker protein distribution suggests that the these impairments
may occur not due to the disruption of the microtubule network or
the dynein-dynactin transport complex, but probably due to the
alterations in the cargo attachment to the transport machinery.
We suggest a further pathogenic mechanism in prion disease
initially involving functional disruption of axonal transport in
rubrospinal motor neurons already on the early stages of prion
neuroinvasion. These results suggest novel targets for diagnostic
and therapeutic approaches, which could be directed at the axonal
transport processes with the focus on the late endosome
attachment to the retrograde transport pathway. Further studies
would allow better characterization of molecular mechanisms
underlying the axonal transport disruption at the prion pathogen-
esis as well as distinct similarities with other neurodegenerative
disorders.
Materials and Methods
Mouse lines used in the study
C57Bl/6 or wild type (wt), Elevage Janvier, Le Genest Saint
Isle, France. Tga20, expresses approximately 10-fold PrP as
compared to the wild type under control of PrP promoter on PrP
knock-out genetic background [32]. Prnp
0/+, possesses one intact
and one disrupted allele of PrP gene [2]. C4/C4 express truncated
D32-93PrP on PrP knock-out genetic background [4].
TG(SHaPrP), expresses approximately 20-fold Syrian hamster
PrP as compared to the wild type hamster under control of PrP
promoter on PrP knock-out genetic background [33].
Mouse inoculation and tracer application
All procedures with laboratory animals were approved by the
committee for the Care and Use of Laboratory Animals of the
Government of Bavaria. Either 30 ml inoculum was injected
intracerebrally (i.c.) or 1 ml inoculum – into right sciatic nerve
(i.n.). 1% RML (1% brain homogenate of terminally scrapie-sick
CD1 mice infected with the Rocky Mountain Laboratory scrapie
strain) was used as mouse prion inoculum, or 1% Sc237 as a
hamster inoculum. 1% brain homogenate from healthy littermates
was used for mock controls. Inoculations into the sciatic nerve
were performed as previously shown [16] with minor changes.
Briefly, animals were anaesthetized with 40 mg/kg Ketanest
(Parke-Davis, c/o Pfizer, Freiburg, Germany) and 40 mg/kg
Rompun (Bayer, Leverkusen, Germany). The right sciatic nerve
was surgically exposed by dislodging M. gluteus superficialis and
M. biceps femoris, placed onto a metal plate (26561 mm) and
1 ml of 1% RML was injected into the nerve with a 33-gauge
Hamilton syringe over a period of 5 min. Great care was taken to
visually control and assure accurate inoculation into the nerve.
After inoculation, the sciatic nerve was repositioned and the lesion
was closed with Vicryl resorbable sutures (Johnson and Johnson,
Du ¨sseldorf, Germany).
Either Fast Blue (FB, Polysciences, Warrington, PA, USA) or
modified double stranded Adeno-Associated Virus [19] expressing
DsRed-Express (AAV-REx) were used to target neurons in the
cortico- and rubrospinal tract. Double stranded Adeno-Associated
virus (AAV) was chosen as a second tracer because it demonstrates
superior and accelerated transduction in vitro and in vivo [21].
Shortly before onset of clinical scrapie (see, Tables S1, S2, S3 and
S4), mice were anesthetized with Ketanest/Rompun, a cut was
made on the level of cervical spinal cord and 1 ml of either 0.1%
FB or AAV (1610
9 virus particles/ml) were injected into the
cervical spinal cord with a 33-gauge Hamilton syringe over a
period of 2 minutes. After inoculation, the wound was closed with
Vicryl resorbable sutures (Johnson and Johnson, Du ¨sseldorf,
Germany).
Sample preparation
The animals (see Tables S1, S2, S3 and S4) were sacrificed
either at terminal stage of the disease, at the time point exactly
matching the tracer injection or a week later – to co-localize REx,
PrP
Sc or different markers. Mice were sacrificed using CO2 and
immediately perfused transcardially with phosphate-buffered
saline (PBS) followed with 4% paraformaldehyde in sodium
phosphate buffer (pH 7.2). The samples for neuron quantification
and immunohistochemistry with subsequent imaging using
confocal microscopy were post-fixed in 4% paraformaldehyde
for 1 hour at 4uC, incubated overnight with 20% sucrose in
phosphate buffered saline (PBS) for cryo-protection at 4uC and
frozen in Tissue Tek (Sakura, Zoeterwoude, The Netherlands)
followed by performing 20 mm-thick cryo-sections. In parallel, the
samples for ultramicroscopy were prepared as reported previously
[18,34]. Briefly, they were post-fixed in 4% paraformaldehyde for
1 hour at 4uC, washed 2 hours in PBS and subsequently in 30%,
50%, 70%, 80%, 96%, and 2 times in 100% alcohol at room
temperature 10 hours each. After 1 h incubation in n-hexane
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were incubated with Clearing Solution (CS, 1 part of benzyl
alcohol and 2 parts of benzyl benzoate, both Sigma-Aldrich
Chemie GmbH, Munich, Germany), 3–4 times 20–30 minutes
each carefully avoiding air contact. The samples were incubated in
CS at room temperature for further 14–18 hours immediately
before imaging.
Confocal microscopy
The tracer-positive neurons or immunohistochemistry in red
nucleus (RN) or motor cortex (MC) were imaged on 20 mm-thick
cryo-sections. The tracer-positive neurons were visualized on a
Leica SP5 (Leica, Mannheim, Germany) laser-scanning confocal
microscope using a 206objective with numerical aperture (NA) of
0.7. Excitation wavelengths of 405 nm and 514 nm were used and
the excited light was analyzed at 500 to 550 and 530 to 580 ranges
for FB and AAV, respectively. This version of confocal microscope
allows for storing exact laser and microscope specifications, which
was done for standardizing the imaging and quantification of
tracer-positive cells. The confocal stacks were taken to visualize
approximately every mm of a given section.
Ultramicroscopy
The home-built ultramicroscopy system was previously de-
scribed [18]. Briefly, it included an Ar Ion Laser (Innova I-308,
Coherent, Santa Clara, CA, USA) and an objective inverter (LSM
Tech, Stewartstown, PA, USA) built into a commercial inverted
microscope (Axiovert 200, Zeiss, Go ¨ttingen, Germany). A 10 mm-
tall light sheet was created by focusing the beam with a cylindrical
lens (focal length 5 cm, Newport, Irvine, CA, USA) and adjusted
with a mirror (Thor Labs, Auburn, CA, USA). To focus the light
sheet, the cylindrical lens was moved using a translation stage
(Standa, Vilnius, Lithuania).
Epiplan 106with 0.2 numerical aperture (NA) and LD
Achroplan 206with 0.4 NA objectives (Zeiss, Go ¨ttingen, Ger-
many) were used in this work. They were placed 14 and 6
millimeters from a home-built 36625 mm rectangular sample
chamber, respectively. The specimen was affixed with Pattex acryl
amide glue (Henkel, Du ¨sseldorf, Germany) to a home-built glass
rod. The sample was positioned with a stepper motor-controlled
stage (Standa, Vilnius, Lithuania) with a feedback-memory system,
XY accuracy of 0.1 mm and rotational accuracy of 0.1 degrees.
The stepper motors were controlled by the software package
LabView (National Instruments, Austin, TA, USA).
The emission light beam was let through the objective inverter
(LSM Tech, Stewartstown, PA, USA), a dichroic mirror (DCLP
555, Chroma, Rockingham, VT, USA) and a band pass filter (HQ
607/75, Chroma, Rockingham, VT, USA) to remove any
scattered excitation light from the laser. A back-illuminated
electron multiplying charge-coupled device (EMCCD) camera
with resolution of 5126512 pixels, 16 mm/pixel (Cascade II,
Photometrics, Tucson AZ, USA) was used in this work. Laser
illumination was synchronized with EMCCD camera exposure, as
previously reported [18]. The exposure time for image acquisition
was 500 ms per frame. Electronic output signal from the EMCCD
camera was filtered and temporally readjusted using a function
generator (Hameg, Mainhausen, Germany). Data acquisition and
storage were administered by the software package MetaMorph
7.1 (Molecular Devices, Downingtown, PA, USA).
Cell quantification and image analysis
The red nucleus (RN) is a center in the midbrain localized
between anteroposterior (bregma) coordinates 24.2 and 23.3
[35]. The RN region was anatomically localized, and typically 35–
40 serial sections were made through this area. The sections were
imaged starting from the caudal part of the RN. We made
confocal z-stacks on each of analyzed serial sections containing
retrogradely labeled neurons to further quantify the labeled cells.
The cell quantification was started upon the appearance of tracer-
positive cells. Typically 10–12 of 20–25 mm-thick serial sections
were analyzed starting from the initial labeled cell appearance.
These sections covered the whole parvicellular and majority of
magnocellular part of RN. Counting ceased upon the disappear-
ance of labeled neurons. FB and REx both localize in the
cytoplasm. Typically the time between tracer application and
sacrificing the mice with subsequent sample analysis was quite long
(up to 163 days), so the traced cells were not visible as a whole, as
was shown elsewhere [36], but contained several irregular
fluorescent objects together forming the cell shape with typical
empty area in the place of nucleus. The cell shapes and sizes were
defined by the NeuN immunostaining. Due to non-uniform
fluorescence of FB and REx in the cytozol, we could not always
apply automated software analysis for cell quantification, but
quantified visually. For un-biased results we compared the data
obtained with two independent researchers. The analysis of z-
stacks enabled the reliable recognition of large pyramidal neurons
with diameters between 12 and 25 mm, discrimination of the signal
from high background (signal-to-background ratio of less than 1.5)
and exclusion of artifacts. We considered the small fluorescent
objects up to 2 to 3 mm in diameter not forming the cellular shapes
as artifacts. These objects were observed in all brain areas, not
only in the RN. A slightly enhanced density of these objects was
observed in the i.n. inoculated Tga20 mice but not in any other
mouse line, and it did not affect the cell count, especially shown by
the co-localization and Region of Interest (ROI) fluorescence
analyses. Additionally we confirmed the localization for the region
of interest using Wisteria floribunda agglutinin (WFA) staining, a
typical RN stain negative for neighboring tissues. Moreover, the
tracer positive cells in RN were co-localized with NeuN and
PGP9.5 neuronal markers. In order to evaluate the size
parameters, we performed control quantification of neurons on
z-stacks from a confocal microscope (see instrumentation) with
NeuN-stained RN cryo-sections, which revealed approximately
10% difference between automated (done using two software
packages, ImageJ and Volocity, see imaging and analysis of
immunohistochemistry experiments) and manual analyses.
The large motor cortex (MC) is located between the anteropos-
terior (bregma) coordinates -1.3 and 2.4. The hindlimb part of the
MC could be mapped by the microstimulation method caudally
from the anteroposterior (bregma) coordinate 21 [37]. For the
analysis of the confocal microscopy images, we took sixty 20 mm
thick serial cryo-sections starting from bregma 21.7 to 21.5
according to the brain anatomy. We examined the sections until the
number of tracer-positive neurons was approximately constant, and
analyzed the first 13 sections, which covered an area of
approximately 260 mm and quantified the labeled cells on every
third section. Analysis of tracer-positive neurons in the MC was
possible for animals traced with AAV-REx only. Two z-stacks for
each side of all quantified MC sections were made on confocal
microscope. In order to normalize the quantification, 5 sections for
each mouse were observed. Z-projection of each stack was
performed on the ImageJ software package (Psion Image, NIH,
Bethesda, MD, USA). Z-projections for each side of the MC were
combined in Adobe Photoshop (Adobe Systems, Munich, Ger-
many) to obtain a complete picture of tracer-positive neurons on the
givenside ofgivensection.Theimagesweresubsequentlycombined
in one stack for each mouse. The quantification parameters
(brightness threshold 85% and size threshold of 60–300 mm
2) were
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NeuN-positive neurons in the MC of mock controls.
The ultramicroscopy stacks were analyzed in a 250 mm-thick
area as reported previously [18]. Briefly, the obtained stacks were
combined in one file and analyzed in ImageJ software with a
brightness threshold of 80% fluorescence and size threshold of 80–
150 mm
2. This area was anatomically localized to the same region.
Furthermore, we demonstrated previously that the ultramicroscopy
technique allowed us to analyze and perform three-dimensional
reconstruction of areas up to 4.2 mm long. The tracer- positive cells
formed an area about 800–900 mm long with a relatively constant
density of labeled cells starting from the bregma coordinate 21.2 to
1.5. These properties did not differ between mock and prion
infected animals, but the cell density was dramatically reduced [18].
All these properties enabled a reliable, uniform localization and
normalization of the cell counting between single probes as well as
between ultramicroscopy and confocal imaging.
Toluidine Blue staining
Toluidine Blue stains the myelin sheath and therefore can be
used to visualize the neuronal projections in the spinal cord. The
5 mm thick paraffin spinal cord sections of wild-type either mock,
i.c. or i.n. prion inoculated mice sacrificed at the terminal stage of
the disease were taken for the experiment. After deparaffinization
and staining in 0.1% Toluidine Blue in 1% NaCl, the sections
were imaged with a light microscope (Leica SP5, Mannheim,
Germany).
Immunohistochemistry
20 mm cryo-sections were used for immunohistochemistry.
Applied antibodies used were: mouse monoclonal NeuN (33 mg/
ml, Millipore, Schwalbach, Germany); goat polyclonal Rab7
(6.7 mg/ml, Santa-Cruz, Heidelberg, Germany); mouse monoclo-
nal p150
GLUED dynactin (8.3 mg/ml, BD Transduction, Heidel-
berg, Germany) and goat polyclonal Notch (6.7 mg/ml, Santa-
Cruz, Heidelberg, Germany).
PrP
Sc was visualized with mouse monoclonal ICSM35 antibody
(11 mg/ml, D-Gen, London, UK). In order to remove PrP
C, cryo-
sections were treated 10 min with 99.9% formic acid.
Secondary antibodies used were: for NeuN – rabbit anti-mouse
IgG coupled with Alexa 546 (1 mg/ml, Invitrogen, Karlsuhe,
Germany); for Rab7 and Notch – biotin-SP-conjugated AffiniPure
rabbit anti-goat IgG (1:100, Dianova, Hamburg, Germany)
combined with Cy5-conjugated streptavidin (1:100, Dianova)
and for p150
GLUED dynactin – biotin-SP-conjugated AffiniPure
rabbit anti-mouse IgG (1:100, Dianova, Hamburg, Germany)
followed by Cy5-conjugated streptavidin.
Imaging and analysis of immunohistochemistry
experiments
Quantification of NeuN-positive neurons was performed on
Volocity (Improvision, Coventry, England) and ImageJ (Psion
Image, NIH, Bethesda, MD, USA) software packages upon
application of a size threshold of 2500 mm
3 (18 mm approximate
cell diameter) for the caudal RN part and 1000 mm
3 (14 mm
approximate cell diameter) – for the middle and the cranial RN
part. For both RN parts the fluorescence threshold was taken as
80% of maximal fluorescence. All co localization analyses were
performed with Volocity software (Improvision, Coventry, Eng-
land) using z-stacks done on 20 mm-thick cryo-sections.
Analysis of the fluorescence in the region of interest (ROI) was
made with ImageJ software (Psion Image, NIH, Bethesda, MD,
USA) on z-stacks previously obtained on cryo-sections stained with
anti-Rab7 antibodies using confocal microscope. The regions of
interest were chosen according to the REx-positive cell debris. The
mean fluorescence values were measured in exactly the same ROI
for appropriate channels throughout the z-stacks. Subsequently,
obtained data was transferred to the Excel program (Microsoft
Deutschland GmbH Unterschleibheim, Deutschland), summa-
rized, and the percentage of the FB to NeuN, REx to NeuN, or
Rab7 to the REx fluorescence in the same ROI was quantified for
each cell. These data were transferred to either Graph Pad Prism
4.0 (GraphPad Software Inc., La Jolla, CA, USA) or OriginPro
(Origin Lab Corporation, Northampton MA, USA) software
packages for making the graphs and statistical analysis.
For the co localization analyses the concatenated confocal z-
stacks were done on ImageJ (Psion Image, NIH, Bethesda, MD,
USA) and subsequently analysed on Volocity software (Improvi-
sion, Coventry, England). The co-localization was shown in the
yellow color throughout the whole manuscript.
The quantification of Ubiquitin- and Notch-positive cells in the
MC was done with ImageJ software (Psion Image, NIH, Bethesda,
MD, USA) on confocal images done on 3 to 5 different wt mice at
145 dpi after i.n. prion infection. The size thresholds of 80–
500 mm
2 and 30–300 mm
2 were taken for ubiquitin and Notch
quantifications, respectively. The 80% fluorescence intensity
threshold was taken for both of them.
Statistics
Unpaired t-tests as well as survival analyses were done using
Graph Pad Prism 4.0 software (GraphPad Software Inc., La Jolla,
CA, USA). N indicates the number of mice or samples in the
experimental set. All error indications are standard deviations.
Supporting Information
Figure S1 Neuropathology in the RN of wt mice infected with
prions into the right sciatic nerve. Paraffin brain sections were
prepared from wt mice immediately before onset of clinical prion
disease (145 dpi) and stained with an antibody against glial
fibrillary acidic protein (GFAP), a marker for activated astrocytes.
Neuropathology is comparable on the sides contralateral and
ipsilateral to prion challenge site. Scale bar: 100 mm.
Found at: doi:10.1371/journal.ppat.1000558.s001 (0.12 MB PDF)
Figure S2 The number of Fast Blue (FB)-positive cells (green),
which co-localize with NeuN positive cells (red), is significantly
different between contralateral and ipsilateral sides of the red
nucleus immediately before the onset of clinical prion disease. The
wild type mice were challenged with prions in the right sciatic
nerve (i. n.) and the FB tracer was injected at 145 days post
inoculation into the spinal cord. The white boxes are areas that
were shown for co-localization analysis on the Figure 3A. Co-
localization of FB and NeuN is shown with yellow. Scale bars,
100 mm.
Found at: doi:10.1371/journal.ppat.1000558.s002 (0.31 MB PDF)
Figure S3 The Regions of Interest (ROI) were defined
according to the REx-positive cells (white lines) for the subsequent
fluorescence analysis. (A) ROI on Fast Blue and NeuN profiles
(see, Figure 3A). (B) ROI on REx and Rab7 profiles (see, Figure 6A
and B). Scale bars, 50 mm.
Found at: doi:10.1371/journal.ppat.1000558.s003 (0.29 MB PDF)
Figure S4 p150GLUED staining reveals diminished immuno-
reactivity in the red nucleus of prion-challenged wt mice
immediately before the onset of prion disease (at 145 dpi upon
i.n. prion challenge) as compared to the mock control. NC -
negative control without primary antibody. Scale bar: 100 mm.
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Figure S5 Dynamitin immunoreactivity in the motor cortex
does not differ between the mock- and prion-inoculated wt mice
immediately before the onset of prion disease (at 145 dpi upon i.n.
prion challenge). NC - negative control without primary antibody.
Scale bar: 100 mm.
Found at: doi:10.1371/journal.ppat.1000558.s005 (0.06 MB PDF)
Figure S6 Toluidine Blue staining of wild type mouse cervical
spinal cord in intracerebrally (i.c.) and intranervously (i.n.)
challenged animals as compared to mock control. Different
degrees of axonal swellings (upper - minimal to no swelling and
lower - more swelling) is visible in the samples from different prion-
infected and control mice. The stainings were done on paraffin
sections from mock and prion challenged mice sacrificed at the
terminal stage of the disease. Scale bar: 100 mm.
Found at: doi:10.1371/journal.ppat.1000558.s006 (0.68 MB PDF)
Table S1 Fast Blue-positive (FB+) neurons in red nucleus (RN)
upon intracerebral (i.c.) prion challenge with 1% RML mouse
prions.
Found at: doi:10.1371/journal.ppat.1000558.s007 (0.01 MB PDF)
Table S2 FB-positive neurons (FB+) in the red nucleus (RN) of
TG(SHaPrP) transgenic mice upon i.c. and i.n. prion challenge
with 1% Sc237 hamster prions.
Found at: doi:10.1371/journal.ppat.1000558.s008 (0.01 MB PDF)
Table S3 FB-positive neurons (FB+) in red nucleus (RN) after
prion challenge into the right sciatic nerve (i.n.) with 1% RML
mouse prions.
Found at: doi:10.1371/journal.ppat.1000558.s009 (0.01 MB PDF)
Table S4 DsRed-Express positive (REx+) neurons in the red
nucleus (RN) upon i.n. challenge with 1% RML mouse prions.
Found at: doi:10.1371/journal.ppat.1000558.s010 (0.01 MB PDF)
Table S5 Tracer-positive and NeuN-positive neurons in red-
nucleus (RN) of wt mice after prion challenge into the right
sciaticnerve (i.n.).
Found at: doi:10.1371/journal.ppat.1000558.s011 (0.01 MB PDF)
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